Skip to main content

JAK/TYK2

    RT @_Castillo_Pedro: Upadacitinib PsA w/axial involvement - post-hoc analysis of SELECT-PsA 1 and S-PsA-2
    Statistically
    2 years 5 months ago
    Upadacitinib PsA w/axial involvement - post-hoc analysis of SELECT-PsA 1 and S-PsA-2 Statistically greater response in axial dz compared to placebo in both dz dx'ed by investigator alone & on investigator + PRO-based criteria https://t.co/YPc5fx9wAR #ACR21 Abst1945 @RheumNow
    RT @drdavidliew: Put those two RF together (essentially nailing down RA pts at risk of cancer):

    age >65 or ever smok
    2 years 5 months ago
    Put those two RF together (essentially nailing down RA pts at risk of cancer): age >65 or ever smoked, all tofa vs TNFi: HR 1.55 (1.05-2.30) age >65 or ever smoked, tofa 5 bid vs TNFi: HR 1.44 (0.93-2.24) neither RF, all tofa vs TNFi: HR 1.16 (0.53-2.55) #ACR21 @RheumNow https://t.co/Uvr4wBhFVF
    RT @ericdeinmd: #ACR21 Ab#1939: Tofa CV Outcome (STAR-RA)
    ▶️Pooled data does not show ⬆️ risk of CVD
    ▶️Trend
    2 years 5 months ago
    #ACR21 Ab#1939: Tofa CV Outcome (STAR-RA) ▶️Pooled data does not show ⬆️ risk of CVD ▶️Trend in pts w prior CVD -HR 1.27 (0.95-1.7), cannot r/o CVD risk in pts w risk factors Less clear than oral surveillance data, but concerns in those w risks https://t.co/JOKNyYVZfX @Rheumnow https://t.co/GGYJfxcqhc
    RT @RichardPAConway: ORAL Surveillance malignancy risk @RADoctor . Numerically higher at both doses tofacitinib compared
    2 years 5 months ago
    ORAL Surveillance malignancy risk @RADoctor . Numerically higher at both doses tofacitinib compared to TNFi . Abstr#1940 #ACR21 @RheumNow https://t.co/uc2k5EaiRq
    RT @drdavidliew: STAR-RA, CV risk
    large insurance datax3

    tofa vs TNFi
    all comers: HR 1.01 (0.83-1.23)
    one CV RF + any M
    2 years 5 months ago
    STAR-RA, CV risk large insurance datax3 tofa vs TNFi all comers: HR 1.01 (0.83-1.23) one CV RF + any MTX: HR 1.24 (0.90-1.69) prev CVD: HR 1.27 (0.95-1.70) not sig but surely okay to say baseline CV risk + tofa makes me a little nervous? @SeoyoungCKim #ACR21 ABST1939 @RheumNow https://t.co/LmmL5zgv9u
    RT @drdavidliew: ORAL Surveillance: MACE and malignancy are getting all the attention...

    but did you know that non-zost
    2 years 5 months ago
    ORAL Surveillance: MACE and malignancy are getting all the attention... but did you know that non-zoster infections are also more likely with tofacitinib vs TNFis? #ACR21 ABST1684 @RheumNow https://t.co/GiBkvPYs4j
    RT @Janetbirdope: Serious infections beyond herpes zoster in both doses of #tofacitinib v #TNFi in Oral Surveillance. No
    2 years 5 months ago
    Serious infections beyond herpes zoster in both doses of #tofacitinib v #TNFi in Oral Surveillance. Note this outcome was not powered to be stat sig. it is a comparison of SIE events #ACR21 abst#1684 @RheumNow https://t.co/uqME6ABXuC